Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.

Autor: Makinoya, Masahiro¹ (AUTHOR), Miyatani, Kozo¹ (AUTHOR) kozo5963@tottori-u.ac.jp, Matsumi, Yoshiaki² (AUTHOR), Sakano, Yu¹ (AUTHOR), Shimizu, Shota¹ (AUTHOR), Shishido, Yuji¹ (AUTHOR), Hanaki, Takehiko¹ (AUTHOR), Kihara, Kyoichi¹ (AUTHOR), Matsunaga, Tomoyuki¹ (AUTHOR), Yamamoto, Manabu¹ (AUTHOR), Tokuyasu, Naruo¹ (AUTHOR), Takano, Shuichi¹ (AUTHOR), Sakamoto, Teruhisa¹ (AUTHOR), Hasegawa, Toshimichi¹ (AUTHOR), Saito, Hiroaki³ (AUTHOR), Nakayama, Yuji⁴ (AUTHOR), Osaki, Mitsuhiko^5,6 (AUTHOR), Okada, Futoshi^5,6 (AUTHOR), Fujiwara, Yoshiyuki¹ (AUTHOR)

Publikováno v: Scientific Reports. 5/2/2024, Vol. 14 Issue 1, p1-12. 12p.

Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1‐Dependent Regulation of MAD2L1 mRNA Stability

Autor: Xiu‐Xia Lu, Yi Que, Jing Yang, Li‐Yuan Le, Qi‐Yan Cai, Bu‐Shu Xu, Dong‐Chun Hong, Yao Liang, Xing Zhang

Publikováno v: Advanced Science, Vol 11, Iss 44, Pp n/a-n/a (2024)

Abstract Patients diagnosed with soft tissue sarcoma (STS) often present at intermediate to advanced stages, with inherently limited therapeutic options available. There is an urgent need to identify novel therapeutic targets. In this study, by scree

Externí odkaz: https://doaj.org/article/a2f46a7575b1440da62a803c2f421886

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis

Autor: Masahiro Makinoya, Kozo Miyatani, Yoshiaki Matsumi, Yu Sakano, Shota Shimizu, Yuji Shishido, Takehiko Hanaki, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Naruo Tokuyasu, Shuichi Takano, Teruhisa Sakamoto, Toshimichi Hasegawa, Hiroaki Saito, Yuji Nakayama, Mitsuhiko Osaki, Futoshi Okada, Yoshiyuki Fujiwara

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)

Abstract Intraperitoneal (IP) chemotherapy with paclitaxel (PTX) for gastric cancer (GC) with peritoneal metastasis (PM) is considered a promising treatment approach, however, there are no useful biomarkers to predict the efficacy of IP therapy. We e

Externí odkaz: https://doaj.org/article/97a461a20ca146be8b96642cf7ce18ea

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.